United States 119th Congress Status: In Committee Bipartisan · 3 D · 2 R cosponsors

S 1097 — Interagency Patent Coordination and Improvement Act of 2025

Last action — Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced March 24, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

Prognosis

Advancing 40% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 5 sponsors

    1 primary, 4 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (3 D · 2 R) — cross-party backing.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Summary

Interagency Patent Coordination and Improvement Act of 2025This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.

Bill Text

What changed in the latest version

12 added · 6 removed

Plain-language change summary

The amendment replaces "section 15" with "section 14" in a reference to the oversight of patents. It also changes the sections' title from "Sec. 15. Interagency Task Force on Patents" to "Sec. 1514. Interagency Task Force on Patents." These changes clarify the specific section of law being referenced and update its designation, which is important for accurately locating the legal text related to the task force on patents.

→
Previous
Latest
1097 Introduced in Senate (IS)] <DOC> 119th CONGRESS 1st Session S.
1097 Reported in Senate (RS)] <DOC> Calendar No.
41 119th CONGRESS 1st Session S.
which was read twice and referred to the Committee on the Judiciary _______________________________________________________________________ A BILL To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.
which was read twice and referred to the Committee on the Judiciary April 10, 2025 Reported by Mr.
Grassley, with amendments [Omit the parts struck through and insert the parts printed in italic] _______________________________________________________________________ A BILL To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.
Not later than 4 years after the date of enactment of this Act, the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office shall submit to the Committee on the Judiciary of the Senate and the Committee on the Judiciary of the House of Representatives a report that contains-- (1) a description of the frequency with which-- (A) information is provided by the Food and Drug Administration to the United States Patent and Trademark Office through the Interagency Task Force on Patents established under section 15 of title 35, United States Code, as added by section 4(a) of this Act, or under processes established by that Task Force;
Not later than 4 years after the date of enactment of this Act, the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office shall submit to the Committee on the Judiciary of the Senate and the Committee on the Judiciary of the House of Representatives a report that contains-- (1) a description of the frequency with which-- (A) information is provided by the Food and Drug Administration to the United States Patent and Trademark Office through the Interagency Task Force on Patents established under section 15 14 of title 35, United States Code, as added by section 4(a) of this Act, or under processes established by that Task Force;
``(6)(A) In exercising the Director's powers and duties under this section relating to patents, and decisions or actions involving patents, for human drugs and biological products, the Director shall, through the Interagency Task Force on Patents established under section 15, consult with the Commissioner of Food and Drugs in the manner described in that section.
``(6)(A) In exercising the Director's powers and duties under this section relating to patents, and decisions or actions involving patents, for human drugs and biological products, the Director shall, through the Interagency Task Force on Patents established under section 14, consult with the Commissioner of Food and Drugs in the manner described in that section.
15.
1514.
``15.
``1514.
<all>
Calendar No.
41 119th CONGRESS 1st Session S.
1097 _______________________________________________________________________ A BILL To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.
_______________________________________________________________________ April 10, 2025 Reported with amendments
⬇ Download PDF
View plain text versions (2)

Action History

  1. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

  2. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

  3. Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

  4. Committee on the Judiciary. Ordered to be reported with amendments favorably.

  5. Introduced in Senate

  6. Read twice and referred to the Committee on the Judiciary. (text: CR S1804-1805)

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 4 co-sponsors · 542 not signed on

Sponsors (1)

Co-sponsors (4)

Not signed on (542)

542 members have not signed on to this bill.

Show all 542 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare technology
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S 1097 do?
Interagency Patent Coordination and Improvement Act of 2025This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.
Who sponsors S 1097?
S 1097 is sponsored by Durbin, Richard J. (Democratic), Tillis, Thomas (Republican), Grassley, Chuck (Republican), Coons, Christopher A. (Democratic), and Welch, Peter (Democratic).
What is the current status of S 1097?
This bill is in committee in the Senate. Introduced March 24, 2025. It must pass committee before a floor vote.
Where can I track S 1097?
Track S 1097 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 1097

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 1097

Last checked for changes 4 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →